Rabies
Conditions
Brief summary
The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2. To assess whether KamRAB interferes with the development of self active antibodies when given simultaneously with active rabies vaccine, as compared to the HRIG comparator product, also given in conjunction with the active rabies vaccine.
Detailed description
This is a prospective, randomized, double-blind, and single period non-inferiority and safety study conducted at a single study site. Subjects were randomized into the following two groups: Group A: KamRAB (20 IU/kg by weight \[bw\]) intramuscular (IM), rabies vaccine (1.0 mL; ≥2.5 IU/mL) IM Group B: Human rabies immune globulin (HRIG) Comparator product (20 IU/kg bw) IM, rabies vaccine (1.0 mL; ≥2.5 IU/mL) IM The primary endpoint was a dichotomous (0-1) variable, defined by reaching an anti-rabies immunoglobulin G (IgG) concentration ≥0.5 IU/mL on Day 14. The primary hypothesis was that the proportion of KamRAB + vaccine recipients with anti-rabies concentration ≥0.5 IU/mL on Day 14 would not be less than the corresponding proportion of HRIG Comparator subjects by as much as 0.1. The safety and tolerability of the study treatments was assessed based on: vital signs and physical examination findings, electrocardiogram (ECG), laboratory findings (hematology, clinical chemistry, and urinalysis) and the occurrence of adverse events (AEs) after drug administration
Interventions
DRUGActive rabies vaccine (US-FDA approved)
A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
Sponsors
Kamada, Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Able and willing to sign an informed consent. * Healthy male or female subjects of 18 - 75 years of age inclusive who have not previously been immunized against rabies. * Ability to comply with completion of a home diary. * No previous exposure to Rabies epidemic, Rabies vaccine and/or Rabies Immune globulin. * No significant abnormalities in serum hematology, serum chemistry and serum immunogenic markers (C3, C4 and C50) according to the Principal Investigator's judgment. * No significant abnormalities in urinalysis according to the Principal Investigator's judgment. * No significant abnormalities in ECG per investigator judgment. * Non-pregnant, non-lactating female subjects, whose screening pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator, or who are more than 5 years post-menopausal or surgically sterilized. * Male subjects must be using at least one effective contraceptive method before study start and throughout the entire duration of the study.
Exclusion criteria
* History or laboratory evidence of immunoglobulin A deficiency. * A history of previous administration of rabies vaccine or HRIG. * History of live virus vaccine administration, e.g., measles vaccine, within the last 3 months. * History of anaphylactic or anaphylactoid hypersensitivity reactions to chicken egg; history of mild allergic reactions to chicken egg, e.g., skin rash only, is not an exclusion criterion * History of hypersensitivity reaction to any of the following components of active rabies vaccine (US-FDA approved) e.g.: neomycin, bovine gelatin, trace amounts of chicken protein, chlortetracycline, and amphotericin B and in accordance with the product insert of the vaccine. * History of hypersensitivity reaction to any of the components in an equivalent active Rabies vaccine. * History of allergy to blood or blood products. * History of bleeding disorders. * Fever at the time of the start of the infusion. (Oral temperature \>38ºC.) * Clinically significant intercurrent illnesses including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study. * Evidence of active systemic infection that required treatment with antibiotics within 2 weeks of the time of drug administration. * Evidence of uncontrolled hypertension (systolic blood pressure of \>150 mm Hg, and/or diastolic blood pressure of \>100 mm Hg). * Heart rate \>120/min. * Weight \> 93.75 kg * Pregnancy and/or lactation. * Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator. * All types of malignancies except for basal and squamous cell (scaly or plate-like) skin cancer or situ cervical carcinoma must be in remission for a minimum of 5 years., For non-melanoma skin cancers and carcinoma in-situ of the cervix may be enrolled if treated and cured at the time of screening. * Previous organ transplant recipient. * Evidence of ongoing infection with Hepatitis A, C, or B, or HIV 1/2. * Presence of psychiatric disorder, other mental disorder or any other medical disorder which might impair the subject's ability to give informed consent or to comply with the requirements of the study protocol. * Previous enrolment in this study. * Participation in another clinical trial within 30 days prior to baseline visit. * Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs in the past 10 years. * History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products. * Known hypersensitivity to any of the ingredients or excipients of the study drugs. * Any other factor that, in the opinion of the investigator, would prevent the subject from complying with the requirements of the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Difference Between KamRAB and HRIG Comparator, in the Proportions of Subjects With Serum Anti-rabies IgG Antibody Concentration ≥ 0.5 IU/mL | Day 14 |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| KamRAB KamRAB 20 IU/kg body weight via IM injection, once on Day 0
Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 | 59 |
| HRIG Comparator Product FDA Approved Commercially Available HRIG Product: IM injection once on Day 0 in the same manner and at the same dosage as KamRAB.
Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 | 59 |
| Total | 118 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 2 | 0 |
| Overall Study | Lost to Follow-up | 0 | 1 |
| Overall Study | Physician Decision | 1 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 1 |
Baseline characteristics
| Characteristic | HRIG Comparator Product | Total | KamRAB |
|---|---|---|---|
| Age, Continuous | 46.3 years STANDARD_DEVIATION 14.5 | 44.8 years STANDARD_DEVIATION 15.35 | 43.3 years STANDARD_DEVIATION 16.15 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants | 4 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 3 Participants | 1 Participants |
| Race (NIH/OMB) White | 53 Participants | 110 Participants | 57 Participants |
| Sex: Female, Male Female | 38 Participants | 75 Participants | 37 Participants |
| Sex: Female, Male Male | 21 Participants | 43 Participants | 22 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 59 | 0 / 59 |
| other Total, other adverse events | 48 / 59 | 51 / 59 |
| serious Total, serious adverse events | 1 / 59 | 0 / 59 |
Outcome results
Primary
The Difference Between KamRAB and HRIG Comparator, in the Proportions of Subjects With Serum Anti-rabies IgG Antibody Concentration ≥ 0.5 IU/mL
Time frame: Day 14
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| KamRAB | The Difference Between KamRAB and HRIG Comparator, in the Proportions of Subjects With Serum Anti-rabies IgG Antibody Concentration ≥ 0.5 IU/mL | 55 Participants |
| HRIG Comparator Product | The Difference Between KamRAB and HRIG Comparator, in the Proportions of Subjects With Serum Anti-rabies IgG Antibody Concentration ≥ 0.5 IU/mL | 58 Participants |
Comparison: The null hypothesis was that Cp ≤ -0.1.90% CI: [-0.082, 0.031]